A comparison of radiation treatment given 6 days a week versus radiation treatment given 5 days a week along with three-weekly chemotherapy in advanced cancers of the head and neck expressing the EGFR mutation

Concurrent chemoradiation versus accelerated radiation in EGFR positive locally advanced squamous cell carcinoma of the head and neck: A randomized open label clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/04/013311

Enrollment

Registered

2018-04-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- EGFR overe expressed locally advanced squamous cell carcinoma of head and neck,

Interventions

Intervention1: Accelerated radiation compared with concurrent chemoradiation in head and neck cancer.: Accelerated radiation , i.e , 6 days a week radiation compared with concurrent chemoradiation , i

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with histology proven EGFR overexpressed squamous cell carcinoma of head and neck region. 2. No previous chemotherapy of radiotherapy for head and neck cancer. 3. No previous surgery except biopsy. 4. Informed consent.

Exclusion criteria

Exclusion criteria: 1. Evidence of systemic metastasis. 2.Histologically other than squamous cell carcinoma. 3. Pregnancy and lactation. 4. Evidence of uncontrolled co-morbidities like uncompensated renal, cardiac, hepatic and respiratory disease.

Design outcomes

Primary

Measure	Time frame
Local controlTimepoint: Local control after 6 weeks of completion of treatment.	—

Secondary

Measure	Time frame
1. Acute toxicities. 2. Late toxicities 3. Recurrence. 4. Death due to any cause.Timepoint: 1. Acute toxicities - weekly during treatment and 6 weeks after completion of treatment. 2. Late toxicities - every three monthly after 6 months of completion of treatment. 3. Recurrence - every three monthly after 6 months of completion of treatment. 4. Whenever the primary investigator get to know the news of death.	—

Measure

Time frame

1. Acute toxicities. 2. Late toxicities 3. Recurrence. 4. Death due to any cause.Timepoint: 1. Acute toxicities - weekly during treatment and 6 weeks after completion of treatment. 2. Late toxicities - every three monthly after 6 months of completion of treatment. 3. Recurrence - every three monthly after 6 months of completion of treatment. 4. Whenever the primary investigator get to know the news of death.

—

Countries

India

Contacts

Public ContactDr Nibedita Biswas

Medical College Kolkata

asitrdeb@rediffmail.com9830583960

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026